ACHL — Achilles Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Achilles Therapeutics Provides Interim Phase I/IIA Update On Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Achilles Therapeutics Reports Q1 2023 Financial Results And Recent Business Highlights
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Achilles Therapeutics Plc Receives Nasdaq Deficiency Letter
Brief: Achilles Therapeutics Gives Positive Phase I/IIa Update On CNet At ESMO IO
Brief: Achilles Therapeutics Announces Grant Of US Patent On Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
Brief: Achilles Therapeutics Reports Third Quarter Financial Results
Brief: Achilles Therapeutics reports Q2 results
Brief: Achilles Therapeutics Reports First Quarter 2022 Financial Results And Recent Business Highlights
Brief: Achilles Therapeutics Doses First Patient With Higher-Dose Cnet In Phase I/Iia Chiron Trial In Advanced Nsclc
Achilles Therapeutics rises on clinical manufacturing expansion in U.S., UK
Brief: Achilles Therapeutics Reports Manufacturing Expansion in UK, Partnership for Manufacturing in U.S.
Brief: Achilles Therapeutics Reports Fourth Quarter And Year-End 2021 Financial Results And Recent Business Highlights
Brief: Achilles Therapeutics Strengthens Scientific Advisory Board With Appointment Of Alena Gros And Ben Creelan